Search - tctmd.com

Displaying 221 - 240 of 329

Sort: Relevancy | Date

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

News Daily News

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Yael L. Maxwell

November 07, 2019

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

Pacemaker-Based Approach Tricks the Body Into Lower BP: MODERATO II

News Conference News TCT 2019

Pacemaker-Based Approach Tricks the Body Into Lower BP: MODERATO II

October 09, 2019

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

News Conference News ESC 2019

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

September 09, 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

August 20, 2019

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

TCTMD’s Top 10 Most Popular Stories for July 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

July 31, 2019

Chest Pain Rule-Out? For Two ED Scores, It’s a Draw

News Conference News SCCT 2019

Chest Pain Rule-Out? For Two ED Scores, It’s a Draw

Yael L. Maxwell

July 19, 2019

Microvascular Disease Quadruples Risk of Leg Amputation

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

July 08, 2019

Vitamin D for CV Risk? Think Twice, Meta-analysis Confirms

News Daily News

Vitamin D for CV Risk? Think Twice, Meta-analysis Confirms

Marcus A. Banks

June 21, 2019

No Need for Niacin? Meta-analysis Argues the End Is Nigh

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

News Daily News

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

April 17, 2019

Visit-to-Visit BP Variability Linked to Coronary Plaque Progression, Adverse Outcomes

News Daily News

Visit-to-Visit BP Variability Linked to Coronary Plaque Progression, Adverse Outcomes

April 11, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.